Monday, 11 May 2015 10:09

Measuring Circulating Tumor DNA for Recurrence in DLBCL

Written by 
Rate this item
(1 Vote)
Written interview with Dr. Mark Roschewski MD and Dr Wyndham H Wilson MD-PhD from National Cancer Institute. They nvestigated the ability of a blood-based assay to monitor patients with DLBCL during and after their initial therapy. The assay studied amplifies and quantifies small amounts of circulating tumor DNA from the patient
Read 296030 times


Global Database Search

 knowyoursubtype iconb   facebook2 twitter 4 512 reverse youtube1

logo europe




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 05/30/17. Copyright ┬ę 2017 Lymphoma Coalition. All rights reserved.